Acceleron Pharma (XLRN) PT Lowered to $68 at H.C. Wainwright

Acceleron Pharma (XLRN) PT Lowered to $58 at Oppenheimer

Oppenheimer analyst Leland Gershell lowered the price target on Acceleron Pharma (NASDAQ: XLRN) to $58.00 (from $59.00) while maintaining a Outperform rating.

Acceleron Pharma (XLRN) PT Lowered to $52 at Citi

Citi analyst Yigal Nochomovitz lowered the price target on Acceleron Pharma (NASDAQ: XLRN) to $52.00 (from $61.00) while maintaining a Buy rating.

After-Hours Movers 09/16: (ACRS) Higher; (FNKO) (XLRN) (DRQ) Lower (more...)

Today's After-Hours Movers

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) 50.9% HIGHER; announced positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution (A-101 45% Topical Solution), an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the primary and all secondary efficacy endpoints, achieving clinically and... More

Acceleron Pharma (XLRN) Phase 2 Trial of ACE-083 in Patients with FSHD Did Not Achieve Functional Secondary Endpoints

Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.

Although ACE-083 demonstrated a robust, statistically significant increase in mean total muscle volume, the primary endpoint of the trial, the increase failed to translate to statistically significant improvements in functional tests. As a result, Acceleron will not conduct further clinical trials of ACE-083 in... More